A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.
List view / Grid view
Next Generation Sequencing (NGS)
Filter the results
Next-generation sequencing (NGS) has become the method of choice for many researchers responding to infectious disease outbreaks and in the present coronavirus pandemic. Here, Pushpanathan Muthuirulan discusses the potential of NGS for rapid diagnosis and explores some of the emerging high-throughput approaches using NGS as a readout for the detection…
Genomics England has launched a next-generation genomic research platform that will play a key role in the response to COVID-19. It is hoped this research environment will transform how genomic data is made usable for global biopharma and academic scientists, providing world‑class patient data security, while enabling the flexibility required…
Responding efficiently to urgent situations is of utmost importance in times of crisis. Dr Suvarna Gandlur, Associate Director of Takara Bio’s next-generation sequencing (NGS) portfolio, discusses how the company is contributing to the COVID-19 effort and supporting the scientific community.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
Application note: A complete next-generation sequencing workflow for circulating cell-free DNA isolation and analysis
Circulating cell-free DNA (cfDNA) has been shown to have potential as a noninvasive substrate for the detection and monitoring of tumour cells. As circulating tumour DNA is often present at low frequencies within cfDNA, targeted sequencing is an optimal tool for mutation detection.
A team of researchers have demonstrated a new way to sequence proteins that are much more sensitive than existing technology, identifying individual protein molecules rather than requiring millions of molecules at a time
Takara Bio has played a major role in the development of single-cell genomics with the launch of kits such as the automation-ready Smart-seq HT, with a simplified 4-steps protocol. In addition, to meetthe demand for using RNA-seq for degraded clinical samples, we have expanded our offering with a complete sequencing…
6 September 2018 | By Takara Bio
The data presented in this application note demonstrates how SMARTer ICELL8 Single-Cell System can be used to generate high-quality RNA-seq libraries that provide full-length transcript sequence information from hundreds of single cells in parallel...